Merck KGaA Engages in Acquisition Talks with SpringWorks Therapeutics

Merck KGaA has confirmed ongoing discussions with SpringWorks Therapeutics, Inc. aimed at a potential acquisition. The news follows press reports indicating negotiations, with the parties discussing a share price around USD 47. However, Merck cautions that no final decisions or binding agreements have been made to date. The potential acquisition aligns with Merck's ongoing strategy to enhance its portfolio through strategic acquisitions.

Merck is a major entity listed on the DAX index, with its shares also traded on several international exchanges. This potential move underscores Merck's interest in expanding its footprint in the therapeutic sector. Stakeholders are advised to stay tuned for further developments as the companies continue their dialogues.